Aktienanalyse zu Biohaven Ltd. (BHVN)BHVNBiohaven Ltd.

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and Targeted Removal of Aberrant Protein (TRAP) extracellular protein degradation for immunological diseases; and myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases, including obesity. Its pipeline includes TYK2/JAK1 Inhibitor (brain-penetrant), IgG Degrader, Gd-IgA1 TRAP Degrader, Taldefgrobep Alfa, Kv7 Activator, TRPM3 Antagonist FGFR3 ADC, CD30 ADC, Trop2 ADC +/- PD1, and others. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Biohaven Ltd is a good buy right now due to its recent $795 million licensing deal with SK Biopharmaceuticals, which significantly enhances its liquidity and supports R&D initiatives. The stock has shown a strong upward momentum, with a 5-day change of +11.26% and a year-to-date change of +42.16%. However, the company has reported negative net income figures, with a projected loss of -130 million in Q1 2026, indicating ongoing financial challenges. Overall, the positive catalysts from the licensing deal and the potential for future revenue growth outweigh the risks associated with its current financial performance.

5 analysts cover BHVN: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 18.00.